A RELATIVELY SAFE WAY TO DOUBLE YOUR MONEY IN BIOTECH - IN JUST 30 DAYS By Porter Stansberry
Conventional wisdom holds that you should only invest in a biotech company if you've got a strong stomach for risk and lots of time... But you won't need either of those things in this case. In fact, the two big uncertainties most biotech investors face are already out of the way. 1. Phase III clinical trials are finished and the clinical endpoints were met. 2. The FDA has agreed to pass judgment on this new drug no later than the end of next month. Normally, given the company's outstanding trial results, all of the opportunity in the stock would be gone. And, some of the opportunity is gone - you're not going to make ten times your money here. But the stock in question is still down 50% from its 2001 offering price... And that means, you've got a reasonable chance to double your money in about a month on the prospects of good news from the FDA. Your opportunity comes courtesy of the bear market in biotech, which has even pushed down good companies with solid financials and proven drugs. But not even this market will ignore FDA approval for a new blockbuster drug. Thus, you've got three things going right for you: an immediate deadline at the FDA, detailed clinical trial results and a violently oversold market for biotech companies. And that's why this month's Diligence conference call will feature a rare kind of biotech stock: It's a reasonable chance to double your money in 30 days, without taking much risk. * You don't need to wait years and years for the clinical results - they're already finished. * You don't have to worry about new competition. This drug is for a rare indication, an "Orphan Drug. " The FDA will grant seven years of market exclusivity, if approved. * No waiting on the FDA either: the agency must decide by January 29th if this new drug will be sold in the United States. A meeting is to make the decision is scheduled for January 15th. * And, although every investment carries risk, this stock has a raised nearly $300 million of capital, but trades for just $400 million, despite outstanding Phase III results. There's more to the story, of course. For example, this firm landed a full 50/50 joint venture with the world's leading drug maker in this category. That's a strong endorsement, considering most start-up drug companies must settle for meager royalties on their first product. There's also a pipeline with another Phase III drug, and several other qualified Phase I products. On its own the company's pipeline is probably worth the company's $400 million market cap. David Lashmet tells me this company's pipeline is actually worth a lot more than its lead product. He sees potential there to make 30 times your money in the longer-term (say by 2006/2007). Of course, to evaluate any of this, you'll need more than a stockbroker or a specialized newsletter writer. You need a serious scientist. That's why we've retained a Professor Emeritus from Stanford University Medical School to help us evaluate this company's technology. This doctor has authored more than 300 peer reviewed scientific articles. He's a former fellow of the American College of Cardiology. And, though he's retired, he continues to work as an adjunct professor at a major medical college. There are more to his credentials...but I can't give away his identity by telling you what he's best known for. In any case, he'll be on the upcoming Diligence conference call. Feel free to ask him any questions you have about this company's technology. He'll probably know the answer: our doctor has worked with the same kind of drugs that make up this company's pipeline. He can offer you a completely unbiased and thoroughly credentialed opinion on the company's properties. And that's the whole point of the Diligence conference call service: to bring the best, most advanced technological investments to you, in a way that you can understand and profit from. This promises to be one of our safest (and fastest) investments ever. We hope you'll join us for our upcoming call. It will be held, starting at 7:30 PM ET, this coming Monday. We're once again offering a $1,500 discount to join the group. One year's access to all Diligence conference calls is now available for $3,500. You may also pay month-to-month, at $417 per month. To join, please click here: http://www.pirateinvestor.com/Reports/WDILCC03.cfm To remove yourself from our list, reply to this message with "remove" in the subject line, or use this link: http:[EMAIL PROTECTED]
